You are here

Publications

Sort By:

2017
Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..  2017.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Anti-Tumor Innate Immunity.. Cancer Discov.
You M-H, Kim BMo, Chen C-H, Begley MJ, Cantley LC, Lee THo.  2017.  Death-associated protein kinase 1 phosphorylates NDRG2 and induces neuronal cell death.. Cell Death Differ. 24(2):238-250.
Taveira Mde Oliveir, Nabavi S, Wang Y, Tonellato P, Esteva FJ, Cantley LC, Wulf GM.  2017.  Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.. J Cancer Res Clin Oncol.
Zheng Y, Cantley LC.  2017.  Membrane Lipids Speak to Histones.. Mol Cell. 66(2):163-164.
Gupta A, Anjomani-Virmouni S, Koundouros N, Dimitriadi M, Choo-Wing R, Valle A, Zheng Y, Chiu Y-H, Agnihotri S, Zadeh G et al..  2017.  PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.. Mol Cell. 65(6):999-1013.e7.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T et al..  2017.  Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.. Ann Oncol. 28(3):512-518.
Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH et al..  2017.  A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.. Clin Cancer Res. 23(1):26-34.
Trousil S, Chen S, Mu C, Shaw FM, Yao Z, Ran Y, Shakuntala T, Merghoub T, Manstein D, Rosen N et al..  2017.  Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.. J Invest Dermatol.
Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, C Kahn R.  2017.  Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling.. J Biol Chem. 292(13):5608.
Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, Yong R, Murty VV, Asara JM, Cantley LC et al..  2017.  PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition.. Cancer Discov. 7(4):380-390.
Ravez S, Corbet C, Spillier Q, Dutu A, Robin AD, Mullarky E, Cantley LC, Feron O, Frédérick R.  2017.  α-Ketothioamide Derivatives: A Promising Tool to Interrogate Phosphoglycerate Dehydrogenase (PHGDH).. J Med Chem.
2016
Breitkopf SB, Yang X, Begley MJ, Kulkarni M, Chiu Y-H, Turke AB, Lauriol J, Yuan M, Qi J, Engelman JA et al..  2016.  A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2.. Sci Rep. 6:20471.
Shim H, Wu C, Ramsamooj S, Bosch KN, Chen Z, Emerling BM, Yun J, Liu H, Choo-Wing R, Yang Z et al..  2016.  Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.. Proc Natl Acad Sci U S A. 113(27):7596-601.
Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H et al..  2016.  Erratum: Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.. Nature. 540(7631):150.
Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC, Toker A.  2016.  Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.. Nat Cell Biol. 18(5):572-8.
Mullarky E, Lucki NC, Zavareh RBeheshti, Anglin JL, Gomes AP, Nicolay BN, C Y Wong J, Christen S, Takahashi H, Singh PK et al..  2016.  Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.. Proc Natl Acad Sci U S A. 113(7):1778-83.
Zhang L, Luga V, Armitage SK, Musiol M, Won A, Yip CM, Plotnikov SV, Wrana JL.  2016.  A lateral signalling pathway coordinates shape volatility during cell migration.. Nat Commun. 7:11714.
Lien EC, Lyssiotis CA, Cantley LC.  2016.  Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.. Recent Results Cancer Res. 207:39-72.
Wang Y, Begley M, Li Q, Huang H-T, Lako A, Eck MJ, Gray NS, Mitchison TJ, Cantley LC, Zhao JJ.  2016.  Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.. Proc Natl Acad Sci U S A. 113(35):9810-5.
Mullarky E, Lairson LL, Cantley LC, Lyssiotis CA.  2016.  A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase.. Mol Cell Oncol. 3(4):e1164280.
Hopkins BD, Goncalves MD, Cantley LC.  2016.  Obesity and Cancer Mechanisms: Cancer Metabolism.. J Clin Oncol. 34(35):4277-4283.
Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H et al..  2016.  Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.. Nature. 536(7617):479-83.
Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P et al..  2016.  Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.. Proc Natl Acad Sci U S A. 113(30):E4338-47.
Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, Varma G, Hung YPun, Ullas S, Lauring J et al..  2016.  Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.. Cell. 164(3):433-46.

Pages